Pharmacology of Glucosidase Inhibitors

Puls, W.

doi:10.1007/978-3-662-09127-2_17

Cited by 25 publications

(13 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This means that these enzyme complexes are competitively inhibited and that their availability to the oligosaccharides from dietary starch is reduced. Thus, monosaccharide formation decreases and less insulin is required for further metabolisation, leading to a reduction of food-induced postprandial increases in blood glucose and insulin 3,5…”

Section: Acarbosementioning

confidence: 99%

Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations

Rosak¹,

Mertes²

2012

DMSO

186

112

View full text Add to dashboard Cite

The alpha-glucosidase inhibitor acarbose has been used for more than 20 years in the management of hyperglycemia. Owing to its unique mode of action in the gastrointestinal tract, its properties are very different from other antidiabetic medications. Patients on long-term treatment to control a chronic disease are not only interested in good treatment efficacy, but are also even more interested in the safety and side effects of their medications. Significant aspects of acarbose predominantly regarding safety and tolerability in the management of type 2 diabetes and prediabetes are reviewed. It is concluded that acarbose is a convenient long-term treatment option, with benefits for both type 2 diabetics and patients in a prediabetic state.

show abstract

Section: Acarbosementioning

confidence: 99%

Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations

Rosak¹,

Mertes²

2012

DMSO

186

112

View full text Add to dashboard Cite

show abstract

“…In the STOP-NIDDM trial in patients with prediabetes, individuals receiving acarbose had lost about 1.2 kg, compared with individuals receiving placebo [29]. This weight loss cannot be explained by changes in dietary habits [33] and malabsorption [16], than may be rather a consequence of changes in release of incretins as seen in recent results of treatment with GLP 1 analoges. The strongest effect on traits of the metabolic syndrome has been shown for elevated blood pressure.…”

Section: Synergistic Effects On Metabolic Syndromementioning

confidence: 95%

“…There are, however, some differences with respect to the inhibitory efficiency on various alpha-glucosidases, which may be responsible for differences in the frequency of side effects. Acarbose is most effective on glucoamylase, followed by sucrase, maltase, and dextranase [16]. It also inhibits the alpha-amylase, but has no effect on beta-glucosidases, such as lactase.…”

Section: Hba 1cmentioning

confidence: 98%

See 1 more Smart Citation

The Role of Alpha-Glucosidase Inhibitors (Acarbose)

Hanefeld¹,

Schäper²

2007

Pharmacotherapy of Diabetes: New Developments

View full text Add to dashboard Cite

“…Most were mild and occurred within the first few weeks (832 (837,838) reported that acarbose (Bayer Corp., West Haven, CT), an ␣-glucosidase inhibitor, reduced the insulin and glucose response to a mixed meal. Puls et al (839) reported a dose-related inhibition of weight gain in both Wistar and Zucker rats. Similar findings and a reduction in visceral adipose tissue were demonstrated with another ␣-glucosidase inhibitor, AO-128, suggesting that these effects are related to this class of compounds (840,842).…”

Section: Orlistatmentioning

confidence: 99%